Clinical trial
Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic…
NCT00002482 · St. Vincent Medical Center - Los Angeles, Other · Unknown status
Key facts
| NCT number | NCT00002482 |
|---|---|
| Title | Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer |
| Official title | A PHASE I-II TRIAL OF MUROMONAB (OKT-3) WITH LOW-DOSE CYCLOPHOSPHAMIDE |
| Lead sponsor | St. Vincent Medical Center - Los Angeles, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological, Drug |
| Interventions | antibody therapy, biological therapy, muromonab-CD3, cyclophosphamide |
| Start date | Jun 1, 1991 |
| First posted | Jun 28, 2004 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: